Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MannKind Corp MNKD

Healthcare Biotechnology
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the... see more

Recent & Breaking News (NDAQ:MNKD)

MannKind to Present at Bank of America Merrill Lynch 2014 Health Care Conference

GlobeNewswire May 7, 2014

MannKind Corporation to Hold 2014 First Quarter Financial Results Conference Call on May 12, 2014

GlobeNewswire May 5, 2014

Abattis Bioceuticals Corp. Enters Into Share Agreement with Experion

Accesswire April 17, 2014

Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund

Accesswire April 15, 2014

MannKind Updates Status of New Drug Application for AFREZZA(R)

GlobeNewswire April 7, 2014

MannKind Corp.'s Share Value Increases 74% on News of FDA's Preliminary Approval

Accesswire April 3, 2014

FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin

Accesswire April 2, 2014

FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes

GlobeNewswire April 1, 2014

King Digital Entertainment's IPO Sets the Wrong Kind of Record

Accesswire April 1, 2014

Galena Biopharma Inc. Share Value Tumbles on News of SEC Investigation

Accesswire March 19, 2014

MannKind Corporation to Present at Upcoming Conferences

GlobeNewswire February 19, 2014

MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results

GlobeNewswire February 18, 2014

MannKind Corporation to Hold 2013 Fourth Quarter and Full Year Financial Results Conference Call on February 18, 2014

Globe Newswire February 4, 2014

Five Star Equities Issues New Research Reports on CALX, CPST, MG and MNKD

Accesswire January 10, 2014

MannKind Announces Tentative Date of FDA Advisory Committee Review of AFREZZA

Globe Newswire January 10, 2014

MannKind Corporation to Present at the J.P. Morgan 2014 Healthcare Conference

Globe Newswire January 8, 2014

Final Hour Buzz: Gilead Sciences, MannKind Corporation, Facebook Inc, Tiger Oil and Energy

Accesswire December 10, 2013

MannKind Corporation to Present at The Piper Jaffray 25th Annual Healthcare Conference

Business Wire November 27, 2013

MannKind Corporation Reports 2013 Third Quarter Financial Results

Business Wire November 4, 2013

MannKind Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA

Business Wire October 30, 2013